| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/06/2006 | US20060073125 Isolation and use of solid tumor stem cells |
| 04/06/2006 | US20060073124 Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue |
| 04/06/2006 | US20060073123 Adenovirus vectors for immunotherapy |
| 04/06/2006 | US20060073120 IKKalpha and IKKbeta specific inhibitors |
| 04/06/2006 | US20060073119 Methods for treating neurodegenerative disorders |
| 04/06/2006 | CA2582041A1 Recombinant human t2 rnase and uses thereof |
| 04/06/2006 | CA2581969A1 Telomelysin-gfp gene-containing recombinant virus |
| 04/06/2006 | CA2580996A1 Method of treating an inflammatory disease by double stranded ribonucleic acid |
| 04/06/2006 | CA2580126A1 Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
| 04/05/2006 | EP1642987A2 Nucleotide sequences derived from the genomes of the retroviruses HIV-1, HIV-2 and SIV, and their application to the amplification of these viral genomes and to the in vitro diagnosis of infections resulting from these viruses |
| 04/05/2006 | EP1642981A1 RECOMBINANT GENE MEDICINE OF ADENOVIRUS VECTOR AND GENE p53 FOR TREATING PROLIFERATIVE DISEASES |
| 04/05/2006 | EP1642968A2 Composition and methods for the diagnosis of tumours |
| 04/05/2006 | EP1642967A2 Composition and methods for the diagnosis of tumours |
| 04/05/2006 | EP1642909A2 Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof |
| 04/05/2006 | EP1642907A2 Composition and methods for the diagnosis of tumours |
| 04/05/2006 | EP1642906A2 Composition and methods for the diagnosis of tumours |
| 04/05/2006 | EP1641927A2 Induced activation in dendritic cells |
| 04/05/2006 | EP1641926A2 Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases |
| 04/05/2006 | EP1102785A4 COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES |
| 04/05/2006 | EP0963207B1 IL12 for the gene therapy of tumours |
| 04/05/2006 | EP0941364B1 Process aimed at evidencing the state of a malignant cell and process for treatment |
| 04/05/2006 | EP0862453B1 Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis |
| 04/05/2006 | EP0710288B1 Adenoviral vectors for treatment of hemophilia |
| 04/05/2006 | CN1756842A Branched neutral amino acid transporters acting as single molecule |
| 04/05/2006 | CN1756768A Trimeric polypeptide construct to induce an enduring t cell response |
| 04/05/2006 | CN1756569A P53 treatment of papillomarivus and carcinogen-transformed cells in hyperplastic lesions |
| 04/05/2006 | CN1756568A Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
| 04/05/2006 | CN1756535A Microencapsulated materials and method of making same |
| 04/05/2006 | CN1754576A Tumour cell vaccine preparation method |
| 04/05/2006 | CN1249249C Universal antibody target non-virus gene introduction system |
| 04/05/2006 | CN1249248C (-)-strand RNA virus vector for nerce cell |
| 04/05/2006 | CN1249243C Targetted liver cancer AFP gene siRNAs expression carrier and its constructing method and use |
| 04/05/2006 | CN1249242C non-resistance choosing for DNA vaccine carrier and its construction method |
| 04/05/2006 | CN1249233C Surface proteins of chlamydia pneumoniae |
| 04/05/2006 | CN1249087C Novel human G-Protein coupled receptor |
| 04/05/2006 | CN1248740C AIDS virus vaccine with use of sendai virus vector |
| 04/05/2006 | CN1248739C Method for identifying individuals suffering from cellular abnormality |
| 04/05/2006 | CN1248733C Tie2 receptor-induced gene transfer system for treating target tumor genes |
| 04/05/2006 | CN1248731C Combined application of tumor suppressor gene therapy and chemotherapy in preparation of pharmaceutical composition for treating tumor |
| 04/04/2006 | US7022832 Wherein secondary structure disintegrates upon attachment of the oligonucleotide to a target nucleic acid; anticarcenogenic agents, treatment of Ewing's sarcoma |
| 04/04/2006 | US7022831 anticode oligomer treatments for inhibiting growth of cancer cells; complementary to mRNA |
| 04/04/2006 | US7022828 Anticancer agents, antiinflammatory agents, autoimmune disease; modulation of gene expression; nuclear factor kappa B |
| 04/04/2006 | US7022818 of given amino acid sequence; use as a target for drug screening of antagonists or agonists of said receptor; receptor can bind persephin |
| 04/04/2006 | US7022525 Process of making a compound by forming a polymer from a template drug |
| 04/04/2006 | US7022496 Use of gene product of adenovirus early region 4 ORF-6 to inhibit repair of double-strand breaks in DNA |
| 04/04/2006 | US7022490 Myc-binding zinc finger proteins, their preparation and their use |
| 04/04/2006 | US7022474 Nucleotide sequences coding polypeptide for use in tumor therapy |
| 04/04/2006 | US7022336 Methods for attaching proteins to lipidic microparticles with high efficiency |
| 04/04/2006 | US7022328 Therapeutic and diagnostic compositions |
| 04/04/2006 | US7022321 Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system |
| 04/04/2006 | US7022320 Eliciting an immune response by administering a vector construct which comprising a recombinant polynucleotide, able encoding a Mycobacterium tuberculosis antigen in human; administering antigen protein, or live attenuated vaccine; gold core carrier; dna vaccines |
| 04/04/2006 | US7022319 Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy |
| 04/04/2006 | US7022313 Hydrogel particle formulation |
| 04/04/2006 | CA2379521C Methods to identify compounds that modulate rage |
| 04/04/2006 | CA2120503C The regulation of systemic immune responses utilizing cytokines and antigens |
| 03/30/2006 | WO2006034433A2 Delivery of polynucleotides |
| 03/30/2006 | WO2006034348A2 Enhanced antisense oligonucleotides |
| 03/30/2006 | WO2006033999A2 Modified adenovirus containing a fiber replacement protein |
| 03/30/2006 | WO2006033933A2 Antisense antiviral compound and method for treating ssrna viral infection |
| 03/30/2006 | WO2006033854A2 Aptamers to von willebrand factor and their use as thrombotic disease therapeutics |
| 03/30/2006 | WO2006033689A2 Aav mediated gene delivery to cochlear cells |
| 03/30/2006 | WO2006033669A2 Method of modulating vascularization |
| 03/30/2006 | WO2006032528A1 Prohibitin as target for cancer therapy |
| 03/30/2006 | WO2006008142A8 Diagnosis and therapy of psoriasis vulgaris |
| 03/30/2006 | WO2005120580A3 Compositions and methods for treatment of fibro-proliferative disorders |
| 03/30/2006 | WO2005117994A9 Bmp pathway methods and compositions |
| 03/30/2006 | WO2005077333A3 Gel-based delivery of recombinant adeno-associated virus vectors |
| 03/30/2006 | WO2005071093A3 Chimpanzee adenovirus vaccine carriers |
| 03/30/2006 | WO2005068638A3 Promoter |
| 03/30/2006 | WO2005056795A3 Hif oligonucleotide decoy molecules |
| 03/30/2006 | WO2005048993A3 Minimization of drug oxidation in drug irradiated excipients formulations |
| 03/30/2006 | WO2005032512A3 Capsules of multilayered neutral polymer films associated by hydrogen bonding |
| 03/30/2006 | WO2004070012A3 Cell-killing molecules and methods of use thereof |
| 03/30/2006 | WO2004065932A3 Methods of identifying modulators of cellular glycosylation using gtrap3-18 |
| 03/30/2006 | WO2004043398A3 Modulation of jumonji expression |
| 03/30/2006 | US20060069246 Tumor necrosis factor receptor related proteins Tango-63d and Tango-63e |
| 03/30/2006 | US20060069242 Neurotrophic factor receptor |
| 03/30/2006 | US20060069239 Epididymis-specific gene as potential contraceptive target |
| 03/30/2006 | US20060069057 Medicaments containing xenogeneic oligo- and/or polyribonucleotides |
| 03/30/2006 | US20060069056 Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
| 03/30/2006 | US20060069055 Delivery of polynucleotides |
| 03/30/2006 | US20060069054 Compositions and methods for the therapy and diagnosis of breast cancer |
| 03/30/2006 | US20060069053 Methods and compositions for enhancing cartilage repair |
| 03/30/2006 | US20060069052 DNA vaccines that expresses mutant ADP-ribosyItransferase toxins which display reduced, or are devoid of, ADP-ribosyltransferase activity |
| 03/30/2006 | US20060069051 AChE antisense oligonucleotide as an anti-inflammatory agent |
| 03/30/2006 | US20060069050 Methods and compositions for mediating gene silencing |
| 03/30/2006 | US20060069049 Methods and reagents related to foxo |
| 03/30/2006 | US20060069025 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 03/30/2006 | US20060069023 Animal model for studying hormone signalling and method of modulating the signalling |
| 03/30/2006 | US20060068453 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 03/30/2006 | US20060068442 immunogens; tumor antigens; devoid of immunosuppressive domain; fusion proteins; immunotherapy |
| 03/30/2006 | US20060068439 Ucp4 |
| 03/30/2006 | US20060068438 Identification of gene expression alterations underlying the aging process in mammals |
| 03/30/2006 | US20060068386 Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof |
| 03/30/2006 | US20060067948 Viral vectors |
| 03/30/2006 | US20060067943 Stabilization of alum-adjuvanted immunologically active agents |
| 03/30/2006 | US20060067938 Methods for the treatment of osteoarthritis and compositions thereof |
| 03/30/2006 | US20060067935 Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
| 03/30/2006 | US20060067932 Antagonists specific for denatured collagen and methods of using same |
| 03/30/2006 | US20060067929 Administering a modified Clostridial toxin with a proteolytic domain; a translocation domain and an orphanin targeting moiety; the HC domain is removed or modified to reduce the targeting of the modified Clostridial toxin to the neuromuscular junction. |